This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CBT-501

CBT Pharmaceuticals

Drug Names(s): CBT-501

Description: CBT-501 is a novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells.

Deal Structure: CBT and Genor
World-wide rights are retained by CBT and China rights have been granted to Genor BioPharma. No additional details have been released.

Partners: Genor Biopharma Co. Ltd.


CBT-501 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug